Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA
Widespread uptake of ICs will require a multi-stakeholder collaboration to overcome common barriers, as a one-size-fits-all approach is insufficient for diverse stakeholder needs. Establishing industry-wide contracting principles and practices may help bridge differences in opinions and build trust between contracting parties, allow stakeholders to share lessons from early adopters, and support efficient contracting processes that promote consistent and equitable patient access to GTs while ensuring healthcare system sustainability.
Authors
- Jonathan D. Campbell (ORCID: https://orcid.org/0000-0001-6539-1258)
- James T. Kenney
- Jacqlyn Riposo
- Theresa Schmidt (ORCID: https://orcid.org/0000-0002-3550-4060)
- Tyler D. Wagner (ORCID: https://orcid.org/0000-0001-7248-4890)
- Kendra M. Gould
- Claire M. Csenge
Institutions
- National Health Council (US)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1007/s40273-025-01563-3
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Pharmaceutical Council